Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure

The perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sylwia Nawrocka-Millward, Jan Biegus, Magdalena Hurkacz, Mateusz Guzik, Marta Rosiek-Biegus, Ewa Anita Jankowska, Piotr Ponikowski, Robert Zymliński
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	de novo AHF acute decompensated chronic HF heart failure biomarkers Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/920fb990e9ae42aabb5cdbfb26c9ff32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:920fb990e9ae42aabb5cdbfb26c9ff32
record_format	dspace
spelling	oai:doaj.org-article:920fb990e9ae42aabb5cdbfb26c9ff322021-11-25T16:53:59ZDifferences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure10.3390/biom111117012218-273Xhttps://doaj.org/article/920fb990e9ae42aabb5cdbfb26c9ff322021-11-01T00:00:00Zhttps://www.mdpi.com/2218-273X/11/11/1701https://doaj.org/toc/2218-273XThe perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF). Accordingly, distinct AHF profiles with differing underlying pathophysiologies of disease progression can be shown. We compared a range of selected biomarkers in order to better describe the profile of de novo AHF and ADHF, including the inter alia—serum lactate, bilirubin, matrix metallopeptidase 9 (MMP-9), follistatin, intercellular adhesion molecule 1 (ICAM-1), lipocalin and galectin-3. The study comprised 248 AHF patients (de novo = 104), who were followed up for one year. The biomarker data of the de novo AHF and ADHF profiles was then compared in order to link biomarkers to their prognosis. Our study demonstrated that, although there are similarities between each patient profile, key biomarker differences do exist—predominantly in terms of NTproBNP, serum lactate, bilirubin, ICAM-1, follistatin, ferritin and sTfR (soluble transferrin receptor). ADHF tended to have compromised organ function and higher risks of both one-year mortality and composite endpoint (one-year mortality or rehospitalization for heart failure) hazard ratios (HR) (95% CI): 3.4 (1.8–6.3) and 2.8 (1.6–4.6), respectively, both <i>p</i> < 0.0001. Among the biomarkers of interest: sTfR HR (95% CI): 1.4 (1.04–1.8), NGAL<sub>(log)</sub> (neutrophil gelatinase-associated lipocalin) HR (95% CI): 2.0 (1.3–3.1) and GDF-15<sub>(log)</sub> (growth/differentiation factor-15) HR (95% CI): 4.0 (1.2–13.0) significantly impacted the one-year survival, all <i>p</i> < 0.05.Sylwia Nawrocka-MillwardJan BiegusMagdalena HurkaczMateusz GuzikMarta Rosiek-BiegusEwa Anita JankowskaPiotr PonikowskiRobert ZymlińskiMDPI AGarticlede novo AHFacute decompensated chronic HFheart failurebiomarkersMicrobiologyQR1-502ENBiomolecules, Vol 11, Iss 1701, p 1701 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	de novo AHF acute decompensated chronic HF heart failure biomarkers Microbiology QR1-502
spellingShingle	de novo AHF acute decompensated chronic HF heart failure biomarkers Microbiology QR1-502 Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
description	The perception of acute heart failure (AHF) as a single entity is increasingly outdated, as distinct patient profiles can be discerned. Key heart failure (HF) studies have previously highlighted the difference in both the course and prognosis of de novo AHF and acute decompensated chronic HF (ADHF). Accordingly, distinct AHF profiles with differing underlying pathophysiologies of disease progression can be shown. We compared a range of selected biomarkers in order to better describe the profile of de novo AHF and ADHF, including the inter alia—serum lactate, bilirubin, matrix metallopeptidase 9 (MMP-9), follistatin, intercellular adhesion molecule 1 (ICAM-1), lipocalin and galectin-3. The study comprised 248 AHF patients (de novo = 104), who were followed up for one year. The biomarker data of the de novo AHF and ADHF profiles was then compared in order to link biomarkers to their prognosis. Our study demonstrated that, although there are similarities between each patient profile, key biomarker differences do exist—predominantly in terms of NTproBNP, serum lactate, bilirubin, ICAM-1, follistatin, ferritin and sTfR (soluble transferrin receptor). ADHF tended to have compromised organ function and higher risks of both one-year mortality and composite endpoint (one-year mortality or rehospitalization for heart failure) hazard ratios (HR) (95% CI): 3.4 (1.8–6.3) and 2.8 (1.6–4.6), respectively, both <i>p</i> < 0.0001. Among the biomarkers of interest: sTfR HR (95% CI): 1.4 (1.04–1.8), NGAL<sub>(log)</sub> (neutrophil gelatinase-associated lipocalin) HR (95% CI): 2.0 (1.3–3.1) and GDF-15<sub>(log)</sub> (growth/differentiation factor-15) HR (95% CI): 4.0 (1.2–13.0) significantly impacted the one-year survival, all <i>p</i> < 0.05.
format	article
author	Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński
author_facet	Sylwia Nawrocka-Millward Jan Biegus Magdalena Hurkacz Mateusz Guzik Marta Rosiek-Biegus Ewa Anita Jankowska Piotr Ponikowski Robert Zymliński
author_sort	Sylwia Nawrocka-Millward
title	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
title_short	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
title_full	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
title_fullStr	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
title_full_unstemmed	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure
title_sort	differences in the biomarker profile of de novo acute heart failure versus decompensation of chronic heart failure
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/920fb990e9ae42aabb5cdbfb26c9ff32
work_keys_str_mv	AT sylwianawrockamillward differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT janbiegus differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT magdalenahurkacz differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT mateuszguzik differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT martarosiekbiegus differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT ewaanitajankowska differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT piotrponikowski differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure AT robertzymlinski differencesinthebiomarkerprofileofdenovoacuteheartfailureversusdecompensationofchronicheartfailure
_version_	1718412851115196416

Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure

Ejemplares similares